BioHealth Innovation, Inc. Partner Company Developing Novel Non-Viral Gene Therapies for Treatment of Vascular Diseases.
ROCKVILLE, MARYLAND, July 25, 2017 – Artgen, Inc. is pleased to expand its collaboration with the University of Maryland, Baltimore to advance its preclinical program for ART-101 under the Maryland Industrial Partnerships (MIPS) program. The proposal for “Novel targeted imaging applications for PAD” will be supported by a matching contribution from Artgen under the terms of the MIPS award guidelines.
“It has been a very positive experience to partner with Artgen, Inc. and University of Maryland, Baltimore. This initiative supports the overall mission of BHI to advance and foster innovation and company startups within the Maryland region.” said Rich Bendis, BHI President & CEO. “Companies like Artgen are building the next generation of the BioHealth Capital Region (BHCR), and we’re looking forward to supporting their continued success.”
MIPS promotes the development and commercialization of products and processes through industry/university research partnerships. MIPS provides matching funds to help Maryland companies pay for the university research. Projects are initiated by the companies to meet their own research and development goals.
About Artgen, Inc.
Incorporated in 2014, Artgen is developing novel non-viral gene therapies for treatment of vascular diseases. Their lead product candidate, ART-101 is a DNA plasmid designed to be delivered directly to the site of injured tissue with the first indication directed for peripheral artery disease (PAD). ART-101 expresses Vascular Endothelial Growth Factor (VEGF), one of the key regulators of angiogenesis. Artgen’s platform technology has the potential for treatment of other vascular diseases. Artgen is currently licensing IP from the Human Stem Cell Institute https://eng.hsci.ru/home.
About BioHealth Innovation, Inc.
BioHealth Innovation, Inc., is a regional innovation intermediary which supports the transformation of research projects into new business opportunities in partnership with the region’s rich assets, institutions, and entrepreneurial community. BHI achieves this goal by being a catalytic partner in the economic development ecosystem. Learn more at www.biohealthinnovation.org.
# # #
Media contacts:
Rich Bendis
Phone: 301-637-6439, email: rbendis@biohealthinnovation.org
ROCKVILLE, MARYLAND, July 25, 2017 – BioHealth Innovation, Inc. (BHI), would like to thank outgoing Managing Director, Ethan Byler as he leaves the organization for the next stage of his career. Over the past five years, Ethan has been responsible for multiple programs supporting the success of BHI. Ethan’s contributions and accomplishments include managing the EIR program with NIH, coordinating SBIR funding assistance to secure over $13M in non-dilutive funding for BHI startup partners, managing the Germantown and Rockville Innovation Centers, building out the Relevant Health accelerator and BHI LaunchLabs suite, achieving successful federal grants for initiatives at BHI, and supporting the growth of a number of biohealth startups in Montgomery County, Baltimore, and other locations across Maryland.
“BHI wouldn’t be where we are today without the hard work and accomplishments of Ethan Byler,” said Richard Bendis, BHI President and CEO. “Ethan has been a consummate professional, leader, and friend to me and the entire BHI family. We wish him the very best as he and his family move to New Jersey for their next adventure.”
In addition, BHI is pleased to announce the addition of Judy Costello as Managing Director, Economic Development at BHI. A longtime supporter of the region’s entrepreneur and start-up communities, Judy joined the Maryland Department of Commerce as Deputy Director of the BioMaryland Center in 2011. More recently, she served as Director of the department’s Office of BioHealth and Life Sciences. She was with the Business Alliance for fifteen years prior, organizing venture pitch forums, entrepreneur bootcamps, tech transfer showcases, educational seminars, and other programs connecting entrepreneurs, faculty innovators, students, and industry leaders in Maryland, D.C., and Virginia.
Prior to joining the Business Alliance, Costello held positions in economic development, financial services marketing, and university public relations. She is a graduate of Georgetown University, and holds a MBA from Loyola University in Maryland.
“We are excited and very fortunate to have Judy join the BHI team,” said Richard Bendis, BHI President and CEO. “Her knowledge of our industry and region will complement the BHI mission.”
About BioHealth Innovation, Inc.
BioHealth Innovation, Inc., is a regional innovation intermediary which supports the transformation of research projects into new business opportunities in partnership with the region’s rich assets, institutions, and entrepreneurial community. BHI achieves this goal by being a catalytic partner in the economic development ecosystem. Learn more at www.biohealthinnovation.org.
# # #
Media Contact:
Rich Bendis
Phone: 301-637-6439, e-mail: rbendis@biohealthinnovation.org
ROCKVILLE, MARYLAND, July 12, 2017– BioHealth Innovation, Inc. would like to thank Amanda Wilson Hague as she moves on to her next adventure after spending five years with the organization. During her time with BHI, Amanda progressed to the role of Director, Finance & Human Resources. She joined the organization in June of 2012 after working for several years at Rockville Economic Development, Inc. (REDI).
BHI is also proud to announce the addition of Lynne A. Brisbane as Director of Finance and Human Resources. Lynne A. Brisbane has more than 15 years of experience leading accounting and financial teams for both for-profit and nonprofit entities. Most recently she held the role as Director of Finance & Administration/CFO of The IJIS Institute, where her responsibilities included providing strategic leadership in all aspects of the nonprofit whose revenues include grants, contracts, and membership fees. Before her role as IJIS, Lynne held positions as Chief Deputy Treasurer for the Loudon County Government and as an Accountant with MedImmune.
“We are excited to have Lynne join the BHI team,” said Richard Bendis, BHI President and CEO. “Her expertise in both the nonprofit and for-profit worlds will make her a great addition to our team.”
About BioHealth Innovation, Inc.
BioHealth Innovation, Inc., is a regional innovation intermediary which supports the transformation of research projects into new business opportunities. BHI is known for providing commercial assistance to scientists and founders, educating and infusing Maryland’s life science community with new and young entrepreneurs and fueling startups within Central Maryland’s bio-ecosystem by connecting young companies to funding and business resources. Learn more at www.biohealthinnovation.org.
# # #
Media Contact:
Rich Bendis
Phone: 301-637-6439, e-mail: rbendis@biohealthinnovation.org
Sonavex, a Baltimore-based medical device company, has announced a raise of $3M in financing including the first close of its Series A round led by Grey Sky Partners. Recently named Maryland’s 2016 Incubator Company of the Year, Sonavex is focused on improving surgical patient outcomes with point-of-care imaging technologies. Other organizations participating in this financing include CRCM Venture Capital, TEDCO, and the Abell Foundation. Award of a $750k Phase II SBIR grant from the National Science Foundation is also included in the financing. With this influx of capital, Sonavex will be advancing the commercialization of EchoSure, a Doppler ultrasound system, and developing additional ultrasound solutions currently in the company’s pipeline. The press release also announces the addition of Bill Niland, CEO of Harpoon Medical, and Bob Hallenbeck, former executive at Becton Dickinson, to Sonavex’s Board of Directors.
Robust private-sector investment and prudent regulation from policymakers have helped establish Maryland as a cradle of innovation and a leader in the U.S. innovation economy. Few states can match Maryland’s highly skilled workforce, market access and technology-centered policy incentives, and the U.S. Chamber of Commerce ranked Maryland No. 1 in the country for entrepreneurship and innovation.
But continued leadership of the region — and the ability of the region to continue to reap the economic and jobs benefits of innovation — is not a given. It requires constant cultivation and smart action from our elected officials.
Maryland is home to more than 800 life sciences companies, 70 federal labs and 16 colleges and universities, including National Institutes of Health, the Food and Drug Administration, Johns Hopkins University, the University System of Maryland and companies like MedImmune and GlaxoSmithKline. About 6 percent of Maryland’s gross domestic product — $17.6 billion — is generated by the life sciences, and the biotechnology industry in Maryland alone employs about 34,000.
During the most recent legislative session in Maryland, the General Assembly considered a piece of onerous drug pricing legislation that threatened the biopharmaceutical ecosystem in the state while also potentially impeding access to care for Maryland patients.
In the name of “transparency,” the legislation — which would have been the most hostile to industry in the country — imposed complex bureaucratic reporting requirements that disregarded the extraordinary development requirements and complex distribution channels for innovative drugs and therapies.
Read more via the Capital Gazette
BioParks 2017 is an opportunity to learn from biotech industry leaders, who share their data, experience, insights and vision. We will explore trends in life science research, funding resources, the marriage of life science and engineering and global partnership opportunities. Translating discoveries from the laboratory to the market has never been more important.
|
Healable is a Mobile Patient Engagement App that allows health care professionals to communicate with patients via secure and private video consults, text messaging and group messaging. It also allows health care professionals to co-ordinate care by allowing them to communicate with each other and to privately discuss patient cases and share relevant patient records. Patients can use this same platform to create online support groups to support and network with other patients with similar health conditions. |
|
|
TruGenomix Health will launch a revolution in treatment for post-traumatic stress disorder (PTSD), offering better identification of the condition and targeted, individualized treatment options. TruGenomix is the brainchild of two veterans, Yusuf Henriques and Charles Cathlin. The two met in 2006 as scientific reviewers in the FDA’s Center for Devices and Radiological Health and bonded over a shared desire to improve medical treatment for veterans and entrepreneurs’ frustration at the pace of innovation. |
|
